ESC Premium Access

Preparing for a novel era in CV prevention: where do PCSK9 inhibitors fit in lipid management?

Topic: Lipids
Organised by Academic Medical Center Amsterdam. Dept Vascular Medicine and Physicians' Academy for Cardiovascular Education / Course Director: Prof John Kastelein / Supported by unrestricted educational grants from Amgen, Pfizer and Sanofi - Regeneron

Congress Presentation

About the speaker

Professor John Kastelein

Faculty of Medecine - University of Amsterdam, Amsterdam (Netherlands (The))
21 presentations
1 follower

4 more presentations in this session

Introduction - PCSK9 inhibition in clinical lipid management: a critical review of evidence and opportunities.

Speaker: Professor W. Koenig (Munich, DE) Professor K. Ray (London, GB)

Thumbnail

PCSK9, the short track road from discovery as drug target towards the clinic.

Speaker: Professor G. Lambert (SAINT DENIS, RE)

Thumbnail

A clinical perspective on PCSK9 inhibition: what do we know and what can we expect?

Speaker: Doctor P. Ridker (Boston, US)

Thumbnail

Discussion & summary - PCSK9 inhibition in clinical lipid management: a critical review of evidence and opportunities.

Speaker: Professor W. Koenig (Munich, DE) Professor K. Ray (London, GB)

Thumbnail

Access the full session

PCSK9 inhibition in clinical lipid management: a critical review of evidence and opportunities

Speakers: Professor J. Kastelein, Professor W. Koenig, Professor K. Ray, Professor G. Lambert, Doctor P. Ridker...
Thumbnail

About the event

Image

ESC CONGRESS 2016

27 August - 31 August 2016

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk